Culprit vessel only vs immediate complete revascularization in patients with acute ST-segment elevation myocardial infarction: Systematic review and meta-analysis

Clinical Cardiology

Volumn 37, Issue 12, 2014, Pages 765-772

  Sekercioglu, Nigar ^a   Spencer, Frederick A ^a   Lopes, Luciane Cruz ^b   Guyatt, Gordon H ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF SOROCABA   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM;

ACUTE HEART INFARCTION; ATTRIBUTABLE RISK; BARE METAL STENT; BLEEDING; CARDIAC PATIENT; CARDIOGENIC SHOCK; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CONTRAST INDUCED NEPHROPATHY; DRUG ELUTING STENT; FOLLOW UP; HEART DEATH; HEART MUSCLE REVASCULARIZATION; HUMAN; MEDICAL HISTORY; META ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; REVIEW; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SYSTEMATIC REVIEW; ACUTE DISEASE; AGED; ELECTROCARDIOGRAPHY; FEMALE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROCEDURES;

ACUTE DISEASE; AGED; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION;

EID: 84919847980     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.22333     Document Type: Review

References (38)

1. Savonitto S, Ardissino D, Granger CB, et al. Prognostic value of the admission electrocardiogram in acute coronary syndromes. JAMA. 1999;281:707-713.
2. Yeh RW, Sidney S, Chandra M, et al. Population trends in the incidence and outcomes of acute myocardial infarction. N Engl J Med. 2010;362:2155-2165.
3. Zijlstra F, Hoorntje JC, de Boer MJ, et al. Long-term benefit of primary angioplasty as compared with thrombolytic therapy for acute myocardial infarction. N Engl J Med. 1999;341:1413-1419.
4. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet. 2003;361:13-20.
5. The Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO IIb) Angioplasty Substudy Investigators. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. N Engl J Med. 1997;336:1621-1628.
6. Effect of intravenous APSAC on mortality after acute myocardial infarction: preliminary report of a placebo-controlled clinical trial. AIMS Trial Study Group. Lancet. 1988;1:545-549.
7. Baigent C, Collins R, Appleby P, et al. ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. The ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. BMJ. 1998;316:1337-1343.
8. Mercado N, Wijns W, Serruys PW, et al. One-year outcomes of coronary artery bypass graft surgery versus percutaneous coronary intervention with multiple stenting for multisystem disease: a meta-analysis of individual patient data from randomized clinical trials. J Thorac Cardiovasc Surg. 2005;130:512-519.
9. The ISAM Study Group. A prospective trial of Intravenous Streptokinase in Acute Myocardial Infarction (ISAM): mortality, morbidity, and infarct size at 21 days. N Engl J Med. 1986; 314:1465-1471.
10. Mahaffey KW, Wojdyla DM, Pieper KS, et al. Comparison of clinical trial outcome patterns in patients following acute coronary syndromes and in patients with chronic stable atherosclerosis. Clin Cardiol. 2014;37:337-342.
11. Mogabgab O, Wiviott SD, Antman EM, et al. Relation between time of symptom onset of ST-segment elevation myocardial infarction and patient baseline characteristics: from the National Cardiovascular Data Registry. Clin Cardiol. 2013;36:222-227.
12. Bavry AA, Elgendy IY, Petersen JW. Outcomes associated with fractional flow-guided revascularization: a meta-analysis. Clin Cardiol. 2014; doi:10.1002/clc.22314.
13. Bonaca MP, Murphy SA, Miller D, et al. Patterns of long-term thienopyridine therapy and outcomes in patients with acute coronary syndrome treated with coronary stenting: observations from the TIMI-38 Coronary Stent Registry. Clin Cardiol. 2014;37:293-299.
14. Bainey KR, Mehta SR, Lai T, et al. Complete vs culprit-only revascularization for patients withmultivessel disease undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a systematic review and metaanalysis. Am Heart J. 2014;167:1.e12-14.e12.
15. Kornowski R, Mehran R, Dangas G, et al. Prognostic impact of staged versus "one-time" multivessel percutaneous intervention in acute myocardial infarction: analysis from the HORIZONSAMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial. J Am Coll Cardiol. 2011;58:704-711.
16. Claessen BE, Dangas GD, Weisz G, et al. Prognostic impact of a chronic total occlusion in a non-infarct-related artery in patients with ST-segment elevation myocardial infarction: 3-year results from the HORIZONS-AMI trial. Eur Heart J. 2012;33:768-775.
17. Di Mario C, Mara S, Flavio A, et al. Single vs multivessel treatment during primary angioplasty: results of the multicentre randomised Hepacoat for Culprit or Multivessel Stenting for Acute Myocardial Infarction (HELP AMI) Study. Int J Cardiovasc Interv. 2004;6:128-133.
18. Politi L, Sgura F, Rossi R, et al. A randomised trial of target-vessel versus multi-vessel revascularisation in ST-elevation myocardial infarction: major adverse cardiac events during long-term followup. Heart. 2010;96:662-667.
19. Wald DS, Morris JK, Wald NJ, et al. Randomized trial of preventive angioplasty in myocardial infarction. N Engl J Med. 2013;369:1115-1123.
20. Ijsselmuiden AJ, Ezechiels J, Westendorp IC, et al. Complete versus culprit vessel percutaneous coronary intervention in multivessel disease: a randomized comparison. Am Heart J. 2004;148:467-474.
21. Toma M, Buller CE, Westerhout CM, et al. Non-culprit coronary artery percutaneous coronary intervention during acute STsegment elevation myocardial infarction: insights from the APEXAMI trial. Eur Heart J. 2010;31:1701-1707.
22. Dambrink JH, Debrauwere JP, van 't Hof AW, et al. Non-culprit lesions detected during primary PCI: treat invasively or follow the guidelines? EuroIntervention. 2010;5:968-975.
23. Hannan EL, Samadashvili Z, Walford G, et al. Culprit vessel percutaneous coronary intervention versus multivessel and staged percutaneous coronary intervention for ST-segment elevation myocardial infarction patients with multivessel disease. JACC Cardiovasc Interv. 2010;3:22-31.
24. Jeger RV, Pfisterer ME. Primary PCI in STEMI - dilemmas and controversies: multivessel disease in STEMI patients. Complete versus culprit-vessel revascularization in acute ST-elevation myocardial infarction. Minerva Cardioangiol. 2011;59:225-233.
25. Higgins JP, Thompson SG, Spiegelhalter DJ. A re-evaluation of random-effects meta-analysis. J R Stat Soc Ser A Stat Soc. 2009;172:137-159.
26. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924-926.
27. Preiss JC, Timmer A, Zeitz M, et al. Emerging concepts in clinical practice guidelines [article in German]. Z Gastroenterol. 2007;45:1075-1081.
28. Guyatt GH,Oxman AD, Schünemann HJ, et al.GRADEguidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol. 2011;64:380-382.
29. Steg PG, James SK, Atar D, et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012;33:2569-2619.
30. O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;61:e78-e140.
31. Murad MH, Montori VM, Walter SD, et al. Estimating risk difference from relative associationmeasures in meta-analysis can infrequently pose interpretational challenges. J Clin Epidemiol. 2009;62:865-867.
32. Vlaar PJ, Mahmoud KD, Holmes DR Jr, et al. Culprit vessel only versus multivessel and staged percutaneous coronary intervention for multivessel disease in patients presenting with ST-segment elevation myocardial infarction: a pairwise and network meta-analysis. J Am Coll Cardiol. 2011;58: 692-703.
33. Bagai A, Thavendiranathan P, Sharieff W, et al. Non-infarctrelated artery revascularization during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a systematic review and meta-analysis. Am Heart J. 2013;166:684.e1-693.e1.
34. O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127:529-555.
35. Gibson CM, Carrozza JP, Laham RJ. Primary percutaneous coronary intervention in acute ST-elevation myocardial infarction: periprocedural management. Waltham, MA: UpToDate Inc; 2014. Accessed April 10, 2014.
36. Boden WE, O'Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356:1503-1516.
37. Trikalinos TA, Alsheikh-Ali AA, Tatsioni A, et al. Percutaneous coronary interventions for non-acute coronary artery disease: a quantitative 20-year synopsis and a network meta-analysis [published correction appears in Lancet. 2009;374:378]. Lancet. 2009;373:911-918.
38. Zhao Z, Witzenbichler B, Mintz GS, et al. Dynamic nature of nonculprit coronary artery lesion morphology in STEMI: a serial IVUS analysis from the HORIZONS-AMI trial. JACC Cardiovasc Imaging. 2013;6:86-95.